The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma.
Adverse effects
Hepatocellular carcinoma
Lenvatinib therapy
Nitric oxide
Overall survival
Progression-free survival
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
23 Aug 2022
23 Aug 2022
Historique:
received:
28
02
2022
accepted:
05
08
2022
entrez:
23
8
2022
pubmed:
24
8
2022
medline:
26
8
2022
Statut:
epublish
Résumé
Lenvatinib is appropriate for reducing the production of nitric oxide (NO) and facilitating as block angiogenesis. However, to our knowledge, there are no data that support the correlation between NO and clinical response in patients who received lenvatinib therapy for HCC. Therefore, we investigated the correlation between the change rate of NO levels and clinical responses including adverse events (AEs) after lenvatinib therapy for unresectable hepatocellular carcinoma (HCC). This study was conducted using previously collected data from another study. We enrolled 70 patients who received lenvatinib for advanced or unresectable HCC. NO was measured by converting nitrate (NO After lenvatinib administration, a change rate in the NO from 0.27 to 4.16 was observed. There was no difference between the clinical response to lenvatinib and the change rate of NO (p = 0.632). However, the change rate of NO was significantly lower in patients with AEs than in those without AEs (p = 0.030). When a reduction in NO rate of < 0.8 was defined as a clinically significant reduction of NO (CSRN), the CSRN group had significantly worse progression-free survival (PFS) and overall survival (OS) than the non-CSRN group (p = 0.029 and p = 0.005, respectively). Decreased NO levels were associated with the occurrence of AEs and worse prognosis after lenvatinib administration. Change rate in serum NO can be used as predictive markers in patients receiving lenvatinib therapy for HCC.
Sections du résumé
BACKGROUND
BACKGROUND
Lenvatinib is appropriate for reducing the production of nitric oxide (NO) and facilitating as block angiogenesis. However, to our knowledge, there are no data that support the correlation between NO and clinical response in patients who received lenvatinib therapy for HCC. Therefore, we investigated the correlation between the change rate of NO levels and clinical responses including adverse events (AEs) after lenvatinib therapy for unresectable hepatocellular carcinoma (HCC).
METHODS
METHODS
This study was conducted using previously collected data from another study. We enrolled 70 patients who received lenvatinib for advanced or unresectable HCC. NO was measured by converting nitrate (NO
RESULTS
RESULTS
After lenvatinib administration, a change rate in the NO from 0.27 to 4.16 was observed. There was no difference between the clinical response to lenvatinib and the change rate of NO (p = 0.632). However, the change rate of NO was significantly lower in patients with AEs than in those without AEs (p = 0.030). When a reduction in NO rate of < 0.8 was defined as a clinically significant reduction of NO (CSRN), the CSRN group had significantly worse progression-free survival (PFS) and overall survival (OS) than the non-CSRN group (p = 0.029 and p = 0.005, respectively).
CONCLUSION
CONCLUSIONS
Decreased NO levels were associated with the occurrence of AEs and worse prognosis after lenvatinib administration. Change rate in serum NO can be used as predictive markers in patients receiving lenvatinib therapy for HCC.
Identifiants
pubmed: 35999529
doi: 10.1186/s12885-022-10002-x
pii: 10.1186/s12885-022-10002-x
pmc: PMC9396897
doi:
Substances chimiques
Antineoplastic Agents
0
Phenylurea Compounds
0
Quinolines
0
Nitric Oxide
31C4KY9ESH
lenvatinib
EE083865G2
Nitrogen Dioxide
S7G510RUBH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
912Informations de copyright
© 2022. The Author(s).
Références
Neurochem Int. 2002 Aug-Sep;41(2-3):161-70
pubmed: 12020616
Hepatol Res. 2020 Sep;50(9):1083-1090
pubmed: 32515895
Biochemistry (Mosc). 1998 Jul;63(7):766-81
pubmed: 9721329
Liver Int. 2012 Apr;32(4):531-43
pubmed: 22316165
Gastroenterologist. 1995 Sep;3(3):220-33
pubmed: 8535773
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Curr Vasc Pharmacol. 2005 Jan;3(1):81-5
pubmed: 15638785
Free Radic Biol Med. 2020 Jan;146:16-35
pubmed: 31672462
Cancer Sci. 2019 Mar;110(3):1054-1063
pubmed: 30657629
Biochemistry. 1995 Apr 25;34(16):5627-34
pubmed: 7537092
Oncology. 2005;69 Suppl 3:4-10
pubmed: 16301830
Cancers (Basel). 2019 Jul 31;11(8):
pubmed: 31370183
Cell. 2019 Mar 7;176(6):1248-1264
pubmed: 30849371
Liver Cancer. 2019 Oct;8(5):299-311
pubmed: 31768341
Liver Cancer. 2018 Mar;7(1):1-19
pubmed: 29662829
Int J Biochem Cell Biol. 1997 Jun;29(6):857-60
pubmed: 9304799
Rom J Morphol Embryol. 2014;55(2 Suppl):539-43
pubmed: 25178323
Nitric Oxide. 2018 Jan 30;72:1-6
pubmed: 29102546
Sci Rep. 2019 Aug 20;9(1):12101
pubmed: 31431642
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 May 15;851(1-2):257-67
pubmed: 17324645
Sci Rep. 2020 Oct 13;10(1):17054
pubmed: 33051476
Rom J Gastroenterol. 2005 Sep;14(3):225-30
pubmed: 16200231
Liver. 2001 Jun;21(3):161-74
pubmed: 11422779
Mol Med Rep. 2012 Dec;6(6):1261-6
pubmed: 23007408
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
J Clin Gastroenterol. 2011 Aug;45(7):651
pubmed: 21415770
Clin Cancer Res. 2021 Sep 1;27(17):4848-4858
pubmed: 34108184
World J Gastroenterol. 2013 Mar 21;19(11):1707-17
pubmed: 23555159
Anal Biochem. 1997 Jan 15;244(2):208-20
pubmed: 9025936
Eur Cytokine Netw. 2009 Dec;20(4):164-70
pubmed: 20167555
Trends Pharmacol Sci. 2015 Aug;36(8):524-36
pubmed: 26027855
J Hepatol. 2014 Dec;61(6):1321-7
pubmed: 25038487